Home » Stocks » CABA

Cabaletta Bio, Inc. (CABA)

Stock Price: $14.22 USD 1.46 (11.44%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $14.65 +0.43 (3.02%) Jan 22, 7:37 PM
Market Cap 342.07M
Revenue (ttm) n/a
Net Income (ttm) -29.43M
Shares Out 24.04M
EPS (ttm) -10.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $14.22
Previous Close $12.76
Change ($) 1.46
Change (%) 11.44%
Day's Open 12.71
Day's Range 12.61 - 14.72
Day's Volume 174,023
52-Week Range 6.00 - 18.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 days ago

Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from...

GlobeNewsWire - 1 month ago

First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoi...

GlobeNewsWire - 1 month ago

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapi...

GlobeNewsWire - 2 months ago

PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapi...

GlobeNewsWire - 3 months ago

PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell ther...

GlobeNewsWire - 4 months ago

PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell thera...

GlobeNewsWire - 5 months ago

PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell thera...

GlobeNewsWire - 6 months ago

PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T...

Zacks Investment Research - 7 months ago

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 7 months ago

Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases

GlobeNewsWire - 8 months ago

PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therap...

Seeking Alpha - 8 months ago

Cabaletta Bio: Curative Medicines For Autoimmunity

Zacks Investment Research - 9 months ago

Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Market Watch - 1 year ago

Cabaletta Bio Inc. shares slid 18% in their trading debut Friday, after underwriters priced the deal at $11, a full $3 below the $14 to $16 price range.

About CABA

Cabaletta Bio, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blister... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
CEO
Dr. Steven A. Nichtberger
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
CABA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Cabaletta Bio stock is "Strong Buy." The 12-month stock price forecast is 20.33, which is an increase of 42.97% from the latest price.

Price Target
$20.33
(42.97% upside)
Analyst Consensus: Strong Buy